drug adverse effects of phosphodiesterase-5-inhibitors

From Aaushi
Jump to navigation Jump to search

Adverse effects

* downregulation of PDE5 is thought to increase invasiveness of melanoma; however, risk > for stages 0 & 1 but not stages 2-4 & no dose-response effect

* no plausible mechanism for increased risk of BCC

More general terms

References

  1. 1.0 1.1 http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#ED
  2. 2.0 2.1 2.2 2.3 Prescriber's Letter 14(12): 2007 Sudden hearing loss with Viagra, Levitra, Cialis, and Revatio Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=231204&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 Cordell WH et al, Retinal Effects of 6 Months of Daily Use of Tadalafil or Sildenafil Archives of Ophthalmology 2009;127(4):367-373 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19365010
  4. 4.0 4.1 4.2 4.3 4.4 4.5 Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009
  5. Schwenk TL Association Between Erectile Dysfunction Drugs and Malignant Melanoma NEJM Journal Watch. June 23, 2015 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
    Loeb S et al. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015 Jun 23; 313:2449 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26103029
  6. 6.0 6.1 6.2 Etminan M, Sodhi M, Mikelberg FS et al Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US. JAMA Ophthalmol. Published online April 7, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35389459 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2790661